Clinical trials: Lung Disorder
Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
For the phase I component of the trial a classic 3 + 3 dose escalation design will be utilized, with a fixed dose of pembrolizumab and an escalating dose of the lenalidomide.
- Trial name
- NCT02963610
- Testing
- Lenalidomide, Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Cystic Fibrosis
A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
Study to evaluate the efficacy of VX-661 in combination with ivacaftor (IVA, VX-770) through Week 12 in participants with cystic fibrosis (CF) who are heterozygous for the F508del mutation on the CF transmembrane conductance…
- Trial name
- NCT02516410
- Testing
- VX-661 plus ivacaftor combination, Ivacaftor
- Where
- 41 sites in United States, Australia and 5 more
- Volunteers
- 168 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pulmonary Tuberculosis
Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis
The purpose of this study is to assess the safety, early bactericidal activity (EBA) and pharmacokinetics of TBA-7371 in adult participants with rifampicin-sensitive tuberculosis and select dose regimen(s) for future studies.
- Trial name
- NCT04176250
- Testing
- TBA-7371, HRZE
- Where
- 4 sites in South Africa
- Volunteers
- 93 people
- Sponsor
- Gates Medical Research Institute
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management…
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
- Trial name
- PREVAIL (NCT05472090)
- Testing
- TNX-102 SL
- Where
- 29 sites in United States
- Volunteers
- 63 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Asthma
Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation
Comparing one versus two doses of oral dexamethasone for the treatment of asthma in the pediatric emergency department.
- Trial name
- R2D2 (NCT02725008)
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Geoffrey W Jara-Almonte
COVID-19
Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic
The Covid-19 has, in a few weeks, made the world tremble: the number of deaths (mainly elderly and / or co-morbid) continues to increase, the confinement causes the collapsing of the economy and the decline of relationships…
- Trial name
- PAPESCO-19 (NCT04421625)
- Testing
- Diagnostic test for SARS-Cov2 for patients and health staff
- Where
- 3 sites in France
- Volunteers
- 1,102 people, healthy volunteers welcome
- Sponsor
- Institut Cancerologie de l'Ouest
Healthy Participants
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 [CYP]3A4 substrate) in Healthy Adult Participants.
- Trial name
- NCT05032950
- Testing
- Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
Characteristics of Pts Initiating Spiriva Respimat in Asthma
This study is a cross-sectional, non-interventional study based on existing data (NISed).
- Trial name
- NCT03692676
- Testing
- Spiriva Respimat
- Where
- Germany
- Volunteers
- 116,133 people
- Sponsor
- Boehringer Ingelheim
Severe Acute Respiratory Syndrome, Coronavirus
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
- Conditions
- Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
- Trial name
- NCT04449276
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- CureVac
Non-Small Cell Lung Cancer
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy.
- Trial name
- HUDSON (NCT03334617)
- Testing
- Durvalumab, Danvatirsen, Ceralasertib
- Where
- 45 sites in United States, Austria and 6 more
- Volunteers
- 528 people
- Sponsor
- AstraZeneca
Cystic Fibrosis
Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF
The purpose of this study is to determine if inhaled urea can be used to detect the presence of Pseudomonas Aeruginosa in the lungs
- Trial name
- NCT01303068
- Testing
- 13C urea breath test Kit
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Pulmonary Embolism
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.
- Trial name
- RESCUE (NCT04248868)
- Testing
- The Bashir™ Endovascular Catheter, r-tPA
- Where
- 19 sites in United States
- Volunteers
- 109 people
- Sponsor
- Thrombolex, Inc.
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Mechanical Ventilation, Acute Respiratory Distress Syndrome
Retrospective Review of Mechanically Ventilated Patients Using a Continuous Data Collection System.
Today, the electronic medical record, microprocessor mechanical ventilators, and physiologic monitoring are under-utilized when translating research into decision support.
- Conditions
- Mechanical Ventilation, Acute Respiratory Distress Syndrome, Hypoxic Respiratory Failure
- Trial name
- T3 (NCT02184208)
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Boston Children's Hospital
COVID-19
A Study of Silmitasertib (CX-4945) in Healthy Subject
This is a Phase I single center, open-label, parallel design in 30 subjects to evaluate safety and tolerability of CX-4945 200mg QD, 200 mg BID and 400mg BID doses (10 subjects in each regimen) for continuously 5 days in healthy…
- Trial name
- NCT05817708
- Testing
- CX-4945
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Senhwa Biosciences, Inc.
Asthma
Teen Asthma Project
Aims of this study are: 1. To determine the feasibility of implementing the intervention using a peer-assisted asthma day camp for adolescents with asthma. 2.
- Trial name
- TAP (NCT01161225)
- Testing
- Peer-assisted asthma self-management program, Adult-led asthma self-management program
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Rochester
Chronic Graft-versus-host-disease
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received…
- Trial name
- AGAVE-201 (NCT04710576)
- Testing
- Axatilimab
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Syndax Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.
- Trial name
- NCT04926233
- Testing
- Tiotropium bromide + Olodaterol, Sp(t)iolto® Respimat®
- Where
- United States
- Volunteers
- 1,371,146 people
- Sponsor
- Boehringer Ingelheim
Chronic Graft-versus-host Disease
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
- Trial name
- NCT03584516
- Testing
- Itacitinib, Methylprednisolone, Prednisone
- Where
- 133 sites in United States, Austria and 14 more
- Volunteers
- 155 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.